LFST Healthcare

LifeStance Health Group, Inc.

$13.37+0.83%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Medical Care Facilities
Country: United States
Market cap: 5.1B USD
Enterprise value: 4.5B USD
Full-time employees: 8,542

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.24 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.38 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.24 vs peers 0.63) and less liquidity (current ratio 1.38 vs peers 2.59)
About average: profitability and valuation

Ranks #576 of 1,157 healthcare companies (top 50%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
LifeStance Health made a profit per share in its latest year after a loss the year before.
Cash flow well above reported profit. Free cash flow is 3.4× reported profit.
Free cash flow is 3.4× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $213M in 2019 to $1.4B in 2025.
LifeStance Health's fiscal-year revenue rose in each of the five years to 2025, from $213M to $1.4B.

StockQuotient Score

52/ 100

Oct 5 52 → Nov 4 52

Valuation

Is the price right?

42/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield1.0%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score -0.33Sector median: 0.0148 · MAD: 0.0148

EBITDA yield2.4%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score -0.41Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield3.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield28.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

85/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 6.0%

Why

Stronger than most peers on:

▲ EPS growth
▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth18.2%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 1.47Sector median: 0.0584 · MAD: 0.0840

Revenue growth20.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.47Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

47/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin4.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.17Sector median: 0.0706 · MAD: 0.1217

Return on assets2.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.12Sector median: 0.0166 · MAD: 0.0537

Return on invested capital4.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.07Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin33.6%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity3.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.24

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.82Sector median: 0.6250 · MAD: 0.3380

Current ratio1.38×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.87Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.19×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.17Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about LifeStance Health

Is LifeStance Health getting weaker?: Its latest SEC filing (Aug 6, 2026) showed no major changes. Its overall score is unchanged at 52/100 since Oct 28, 2026.
How is LifeStance Health valued vs its peers?: Priced about in line with its peers. Valuation scores 42/100 against 1,393 healthcare peers.
Is LifeStance Health growing?: Yes, faster than most of its peers. Growth scores 85/100 against 1,393 healthcare peers. 3-year revenue growth 18.2% vs a peer median of 5.8% (stronger than 79% of peers).3-year revenue growth 18.2% vs peers 5.8% (stronger than 79% of peers).
How profitable is LifeStance Health?: About as profitable as its peers. Profitability scores 47/100 against 1,393 healthcare peers.
How risky is LifeStance Health?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.24 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.24 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.5B USD	1.6B USD	+6.0%
Net income (12 months)	23.2M USD	50.6M USD	+118.1%
Operating margin	3.0%	4.9%	+1.9 pts
Free cash flow (12 months)	142.6M USD	173.9M USD	+21.9%
Debt	282.8M USD	275.5M USD	−2.6%
Cash	194.8M USD	225.9M USD	+16.0%
Shares outstanding	387.8M	382.1M	−1.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Care Facilities · 27 companies

Valuations in Medical Care Facilities are within their usual range since Jun 2017.

39% of months since Jun 2017 were valued lower than now.
28% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is −61% vs the whole market, against a usual −56%.

Jun 2017Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-42.9%	-24.5%	-17.9%	-2.5%	1.7%	▲ 4.2 pts
Net margin	-46.0%	-25.1%	-17.6%	-4.6%	0.7%	▲ 5.3 pts
Return on assets (ROA)	-15.9%	-9.9%	-8.8%	-2.7%	0.4%	▲ 3.2 pts
Return on equity (ROE)	-19.9%	-14.2%	-13.0%	-4.0%	0.6%	▲ 4.6 pts
Free cash flow margin	-12.7%	-3.1%	-5.4%	6.9%	7.7%	▲ 0.9 pts
Current ratio	2.28×	1.33×	1.11×	1.37×	1.65×	▲ 21%
Debt to equity	0.10×	0.15×	0.20×	0.20×	0.19×	▼ 7.3%
Interest coverage	-7.36×	-10.55×	-8.91×	-1.19×	2.07×	▲ 274%

LFST price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.24 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.38 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.24 vs peers 0.63) and less liquidity (current ratio 1.38 vs peers 2.59)

About average: profitability and valuation

Ranks #576 of 1,157 healthcare companies (top 50%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

LifeStance Health made a profit per share in its latest year after a loss the year before.

Cash flow well above reported profit. Free cash flow is 3.4× reported profit.

Free cash flow is 3.4× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $213M in 2019 to $1.4B in 2025.

LifeStance Health's fiscal-year revenue rose in each of the five years to 2025, from $213M to $1.4B.

Questions investors ask about LifeStance Health

Is LifeStance Health getting weaker?

Its latest SEC filing (Aug 6, 2026) showed no major changes. Its overall score is unchanged at 52/100 since Oct 28, 2026.

How is LifeStance Health valued vs its peers?

Priced about in line with its peers. Valuation scores 42/100 against 1,393 healthcare peers.

Is LifeStance Health growing?

Yes, faster than most of its peers. Growth scores 85/100 against 1,393 healthcare peers. 3-year revenue growth 18.2% vs a peer median of 5.8% (stronger than 79% of peers).3-year revenue growth 18.2% vs peers 5.8% (stronger than 79% of peers).

How profitable is LifeStance Health?

About as profitable as its peers. Profitability scores 47/100 against 1,393 healthcare peers.

How risky is LifeStance Health?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.24 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.24 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.5B USD

1.6B USD

+6.0%

Net income (12 months)

23.2M USD

50.6M USD

+118.1%

Operating margin

3.0%

4.9%

+1.9 pts

Free cash flow (12 months)

142.6M USD

173.9M USD

+21.9%

Debt

282.8M USD

275.5M USD

−2.6%

Cash

194.8M USD

225.9M USD

+16.0%

Shares outstanding

387.8M

382.1M

−1.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-42.9%

-24.5%

-17.9%

-2.5%

1.7%

▲ 4.2 pts

Net margin

-46.0%

-25.1%

-17.6%

-4.6%

0.7%

▲ 5.3 pts

Return on assets (ROA)

-15.9%

-9.9%

-8.8%

-2.7%

0.4%

▲ 3.2 pts

Return on equity (ROE)

-19.9%

-14.2%

-13.0%

-4.0%

0.6%

▲ 4.6 pts

Free cash flow margin

-12.7%

-3.1%

-5.4%

6.9%

7.7%

▲ 0.9 pts

Current ratio

2.28×

1.33×

1.11×

1.37×

1.65×

▲ 21%

Debt to equity

0.10×

0.15×

0.20×

0.19×

▼ 7.3%

Interest coverage

-7.36×

-10.55×

-8.91×

-1.19×

2.07×

▲ 274%